# Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

> **NCT04147286** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of Cape Town** · enrollment: 220 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Atorvastatin 40mg
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04147286
- **Lead sponsor:** University of Cape Town
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2024-08-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04147286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04147286, "Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04147286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*